Should you buy The Reject Shop?

Profit fall casts doubt over future growth.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Following an unexpectedly poor Christmas period, The Reject Shop (ASX: TRS) announced a 16% fall in first-half net profit to $16.9 million, down from $20 million in the prior corresponding period.

Sales for the first half were up 18% to $385 million, due largely to the opening of 33 new stores during the period. Despite trending positively for most of the half, comparable store sales were flat overall, with disappointing sales over the peak weeks leading into Christmas.

As previously announced, the company expects full year net profit to be between $17 million and $18 million. This is down from $19.5 million in the previous year.

Managing Director Chris Byrce said, "We have undertaken a thorough review of all areas of our business to determine the actions required to increase profitability. We have identified a range of initiatives aimed at providing more flexibility to react to current trading and hence become a more proactive business going forward".

The discount variety retailer has grown its network of stores to more than 300, with a target of 400 across Australia. The Reject Shop is known for low-margin products such as confectionery, health and beauty items and other consumables — a strategy that has historically proven successful. However, the recent transition into higher-margin products is proving difficult as the company is exposed more to discretionary consumer spending. 

Foolish takeaway

The Reject Shop has a robust balance sheet, strong operating cash flows and significant growth in planned store openings which provide a strong foundation for future growth.

It has announced a range of initiatives aimed at improving profitability. If it can successfully execute on the announced initiatives, patient investors will be rewarded as the current share price has limited upside priced in.

 

 

Motley Fool contributor Bradley Murphy does not own shares in any of the companies mentioned in this article.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »